Abstract
Once surgical options have been exhausted, systemic therapy is indicated for metastasizing renal cell carcinoma. Until recently this was carried out using mainly immunotherapeutic concepts with unsatisfactory results. Since the majority of clear cell renal cell carcinomas are well vascularised, angiogenetic inhibition offered an alternative therapy goal. To date, four substances have been approved to control angiogenesis in the therapy of renal cell carcinoma: sunitinib, sorafenib, temsirolimus, as well as a combination of bevacizumab and interferon alpha. Other substances, such as everolimus, pazopanib and axitinib, are currently the subject of clinical trials. Initial data on tolerance and efficacy was presented at this years annual conference of the American Society of Clinical Oncology (ASCO). This article examines current therapy options and ASCO data and discusses future trends.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Benzenesulfonates / therapeutic use
-
Bevacizumab
-
Carcinoma, Renal Cell / blood supply
-
Carcinoma, Renal Cell / diagnostic imaging
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / pathology
-
Chemotherapy, Adjuvant
-
Clinical Trials as Topic
-
Disease Progression
-
Drug Therapy, Combination
-
Humans
-
Indoles / therapeutic use
-
Interferon-alpha / therapeutic use
-
Kidney Neoplasms / blood supply
-
Kidney Neoplasms / diagnostic imaging
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / pathology
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Pyridines / therapeutic use
-
Pyrroles / therapeutic use
-
Sirolimus / analogs & derivatives
-
Sirolimus / therapeutic use
-
Sorafenib
-
Sunitinib
-
Tomography, X-Ray Computed
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Benzenesulfonates
-
Indoles
-
Interferon-alpha
-
Phenylurea Compounds
-
Pyridines
-
Pyrroles
-
Niacinamide
-
Bevacizumab
-
temsirolimus
-
Sorafenib
-
Sunitinib
-
Sirolimus